Suppression of integrin α3β1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells

Cancer Research

Volumn 70, Issue 15, 2010, Pages 6359-6367

  Mitchell, Kara ^a   Svenson, Kimberly B ^a   Longmate, Whitney M ^a   Gkirtzimanaki, Katerina ^c,d   Sadej, Rafal ^b   Wang, Xianhui ^a   Zhao, Jihe ^a   Eliopoulos, Aristides G ^c,d   Berditchevski, Fedor ^b   DiPersio, C Michael ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF CRETE   (Greece)

^d INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; KI 67 ANTIGEN; PROSTAGLANDIN E2; SHORT HAIRPIN RNA; VERY LATE ACTIVATION ANTIGEN 3; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CANCER INVASION; CELL COMMUNICATION; DRUG ANTAGONISM; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; CYCLOOXYGENASE 2; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA3BETA1; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; RNA, MESSENGER; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955390123     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4283     Document Type: Article

References (50)

1. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87.
2. Brakebusch C, Bouvard D, Stanchi F, Sakai T, Fassler R. Integrins in invasive growth. J Clin Invest 2002;109:999-1006.
3. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003;20:203-13.
4. Mercurio AM, Bachelder RE, Chung J, et al. Integrin laminin receptors and breast carcinoma progression. J Mammary Gland Biol Neoplasia 2001;6:299-309.
5. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007;25:1637-8.
6. Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 2006;13:113-35.
7. Kreidberg JA. Functions of α3β1 integrin. Curr Opin Cell Biol 2000;12:548-53.
8. Tsuji T. Physiological and pathological roles of α3β1 integrin. J Membr Biol 2004;200:115-32.
9. Morini M, Mottolese M, Ferrari N, et al. The α 3 β 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer 2000;87:336-42.
10. Wang H, Fu W, Im JH, et al. Tumor cell α3β1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J Cell Biol 2004;164:935-41.
11. Lamar JM, Pumiglia KM, DiPersio CM. An immortalization-dependent switch in integrin function up-regulates MMP-9 to enhance tumor cell invasion. Cancer Res 2008;68:7371-9.
12. Chia J, Kusuma N, Anderson R, et al. Evidence for a role of tumor-derived laminin-511 in the metastatic progression of breast cancer. Am J Pathol 2007;170:2135-48.
13. Marinkovich MP. Tumour microenvironment: laminin 332 in squamous-cell carcinoma. Nat Rev Cancer 2007;7:370-80.
14. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004;90:423-9.
15. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004;101:591-6.
16. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002;62:1676-81.
17. Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007;9:210.
18. Stasinopoulos I, O'Brien DR, Wildes F, Glunde K, Bhujwalla ZM. Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res 2007;5:435-42.
19. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-9.
20. Howe LR, Chang SH, Tolle KC, et al. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 2005;65:10113-9.
21. Yiu GK, Toker A. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J Biol Chem 2006;281:12210-7.
22. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
23. Mitchell K, Szekeres C, Milano V, et al. a3b1 integrin in epidermis promotes wound angiogenesis and keratinocyte-to-endothelial-cell crosstalk through the induction of MRP3. J Cell Sci 2009;122:1778-87.
24. Baldwin G, Novitskaya V, Sadej R, et al. Tetraspanin CD151 regulates glycosylation of a3b1 integrin. J Biol Chem 2008;283:35445-54.
25. Sadej R, Romanska H, Baldwin G, et al. CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol Cancer Res 2009;7:787-98.
26. Inoue M, Itoh H, Ueda M, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998;98:2108-16.
27. DiPersio CM, Shah S, Hynes RO. a3Ab1 integrin localizes to focal contacts in response to diverse extracellular matrix proteins. J Cell Sci 1995;108:2321-36.
28. Lundstrom A, Holmbom J, Lindqvist C, Nordstrom T. The role of α2 β1 and α3 β1 integrin receptors in the initial anchoring of MDA-MB-231 human breast cancer cells to cortical bone matrix. Biochem Biophys Res Commun 1998;250:735-40.
29. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 2007;26:525-34.
30. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
31. Davies GL. Cyclooxygenase-2 and chemoprevention of breast cancer. J Steroid Biochem Mol Biol 2003;86:495-9.
32. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
33. Singh-Ranger G, Salhab M, Mokbel K. The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat 2008;109:189-98.
34. Wulfing P, Diallo R, Muller C, et al. Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 2003;129:375-82.
35. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544-51.
36. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001;8:97-114. (Pubitemid 32641352)
37. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
38. Khan KM, Howe LR, Falcone DJ. Extracellular matrix-induced cyclooxygenase-2 regulates macrophage proteinase expression. J Biol Chem 2004;279:22039-46.
39. Itatsu K, Sasaki M, Yamaguchi J, et al. Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-α. Am J Pathol 2009;174:829-41.
40. Bansal K, Kapoor N, Narayana Y, Puzo G, Gilleron M, Balaji KN. PIM2 Induced COX-2 and MMP-9 expression in macrophages requires PI3K and Notch1 signaling. PLoS One 2009;4:e4911.
41. Iyer V, Pumiglia K, DiPersio CM. α3β1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: a novel mechanism of integrin-mediated MMP gene expression. J Cell Sci 2005;118:1185-95.
42. Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 1996;56:4063-70.
43. Boosani CS, Mannam AP, Cosgrove D, et al. Regulation of COX-2 mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis. Blood 2007;110:1168-77.
44. Yauch RL, Berditchevski F, Harler MB, Reichner J, Hemler ME. Highly stoichiometric, stable, and specific association of integrin α3β1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration. Mol Biol Cell 1998;9:2751-65.
45. Berditchevski F, Gilbert E, Griffiths MR, Fitter S, Ashman L, Jenner SJ. Analysis of the CD151-3β1 integrin and CD151-tetraspanin interactions by mutagenesis. J Biol Chem 2001;276:41165-74.
46. Sugiura T, Berditchevski F. Function of α3β1-tetraspanin protein complexes in tumor cell invasion. Evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP-2). J Cell Biol 1999;146:1375-89.
47. Winterwood NE, Varzavand A, Meland MN, Ashman LK, Stipp CS. A critical role for tetraspanin CD151 in α3β1 and α6β4 integrin-dependent tumor cell functions on laminin-5. Mol Biol Cell 2006;17:2707-21.
48. Yang XH, Richardson AL, Torres-Arzayus MI, et al. CD151 accelerates breast cancer by regulating α 6 integrin function, signaling, and molecular organization. Cancer Res 2008;68:3204-13.
49. Zijlstra A, Lewis J, Degryse B, Stuhlmann H, Quigley JP. The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 2008;13:221-34.
50. Yang XH, Flores LM, Li Q, et al. Disruption of laminin-integrin-CD151- focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 2010;70:2256-63.